52 / 220
3. Gregoire V, Lefebvre JL, Licitra L, Felip E. Squamous cell
carcinoma of the head and neck: EHNS-ESMO-ESTRO clini-
cal practice guidelines for diagnosis, treatment and follow-up.
Ann Oncol
. 2010;21(suppl 5):v184-v186.
4. Ang KK, Trotti A, Brown BW, et al. Randomized trial addres-
sing risk features and time factors of surgery plus radiotherapy
in advanced head-and-neck cancer.
Int J Radiat Oncol Biol
Phys
. 2001;51:571-578.
5. Koness RJ, Glicksman A, Liu L, et al. Recurrence patterns
with concurrent platinum-based chemotherapy and accelerated
hyperfractionated radiotherapy in stage III and IV head and
neck cancer patients.
Am J Surg
. 1997;174:532-535.
6. Gourin CG, Watts TL, Williams HT, Patel VS, Bilodeau PA,
Coleman TA. Identification of distant metastases with
positron–emission tomography-computed tomography in
patients with previously untreated head and neck cancer.
Laryngoscope
. 2008;118:671-675.
7. Perlow A, Bui C, Shreve P, Sundgren PC, Teknos TN,
Mukherji SK. High incidence of chest malignancy detected by
FDG PET in patients suspected of recurrent squamous cell car-
cinoma of the upper aerodigestive tract.
J Comput Assist
Tomogr
. 2004;28:704-709.
8. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB.
Recurrence at the primary site in head and neck cancer and the
significance of neck lymph node metastases as a prognostic
factor.
Cancer
. 1994;73:187-190.
9. Salaun PY, Abgral R, Querellou S, et al. Does 18fluoro-fluorodeox-
yglucose positron emission tomography improve recurrence detec-
tion in patients treated for head and neck squamous cell carcinoma
with negative clinical follow-up?
Head Neck
.
2007;29:1115-1120
.
10. Whiting P, Rutjes AW, Dinnes J, Reitsma J, Bossuyt PM,
Kleijnen J. Development and validation of methods for asses-
sing the quality of diagnostic accuracy studies.
Health Technol
Assess
. 2004;8:iii, 1-234.
11. Brkovich VS, Miller FR, Karnad AB, Hussey DH, McGuff HS,
Otto RA. The role of positron emission tomography scans in the
management of the N-positive neck in head and neck squamous
cell carcinoma after chemoradiotherapy.
Laryngoscope
. 2006;
116:855-858.
12. Ceulemans G, Voordeckers M, Farrag A, Verdries D, Storme
G, Everaert H. Can 18-FDG-PET during radiotherapy replace
post-therapy scanning for detection/demonstration of tumor
response in head-and-neck cancer?
Int J Radiat Oncol Biol
Phys
. 2011;81:938-942.
13. Chaiken L, Rege S, Hoh C, et al. Positron emission tomogra-
phy with fluorodeoxyglucose to evaluate tumor response and
control after radiation therapy.
Int J Radiat Oncol Biol Phys
.
1993;27:455-464.
14. Conessa C, Foehrenbach H, Herve´ S, Poncet J-L. FDG-PET
scan in local follow-up of irradiated head and neck squamous
cell carcinomas.
Ann Otol Rhinol Laryngol
. 2004;113:628-635.
15. Fakhry N, Jacob T, Paris J, et al. Contribution of 18-F-FDG
PET for detection of head and neck carcinomas with an
unknown primary tumor.
Ann Otolaryngol Chir Cervicofac
.
2006;123:17-25.
16. Goerres GW, Haenggeli CA, Allaoua M, et al. Direct compari-
son of F-18-FDG PET and ultrasound in the follow-up of
patients with squamous cell cancer of the head and neck.
Nuklearmedizin
. 2000;39:246-250.
17. Goerres GW, Schmid DT, Bandhauer F, et al. Positron emission
tomography in the early follow-up of advanced head and neck
cancer.
Arch Otolaryngol Head Neck Surg
. 2004;130:105-109.
18. Gupta T, Jain S, Agarwal JP, et al. Diagnostic performance of
response assessment FDG-PET/CT in patients with head and
neck squamous cell carcinoma treated with high-precision defi-
nitive (chemo) radiation.
Radiother Oncol
. 2010;97:194-199.
19. Inohara H, Enomoto K, Tomiyama Y, et al. The role of CT and
18F-FDG PET in managing the neck in node-positive head and
neck cancer after chemoradiotherapy.
Acta Otolaryngol
. 2009;
129:893-899.
20. Ito K, Yokoyama J, Kubota K, Morooka M, Shiibashi M,
Matsuda H. 18F-FDG versus 11C-choline PET/CT for the ima-
ging of advanced head and neck cancer after combined intra-
arterial chemotherapy and radiotherapy: the time period during
which PET/CT can reliably detect non-recurrence.
Eur J Nucl
Med Mol Imaging
. 2010;37:1318-1327.
21. Kim SY, Lee S-W, Nam SY, et al. The feasibility of 18F-FDG
PET scans 1 month after completing radiotherapy of squamous cell
carcinoma of the head and neck.
J Nucl Med
. 2007;48:373-378.
22. Kishino T, Hoshikawa H, Nishiyama Y, Yamamoto Y, Mori
N. Usefulness of 3
#
-deoxy-3
#
-18F-fluorothymidine PET for
predicting early response to chemoradiotherapy in head and
neck cancer.
J Nucl Med
. 2012;53:1521-1527.
23. Kitagawa Y, Nishizawa S, Sano K, et al. Prospective compari-
son of 18F-FDG PET with conventional imaging modalities
(MRI, CT, and 67Ga scintigraphy) in assessment of combined
intraarterial chemotherapy and radiotherapy for head and neck
carcinoma.
J Nucl Med
. 2003;44:198-206.
24. Kubota K, Yokoyama J, Yamaguchi K, et al. FDG-PET
delayed imaging for the detection of head and neck cancer
recurrence after radio-chemotherapy: comparison with MRI/
CT.
Eur J Nucl Med Mol Imaging
. 2004;31:590-595.
25. Li P, Zhuang H, Mozley PD, et al. Evaluation of recurrent
squamous cell carcinoma of the head and neck with FDG posi-
tron emission tomography.
Clin Nucl Med
. 2001;26:131-135.
26. McCollum AD, Burrell SC, Haddad RI, et al. Positron emis-
sion tomography with 18F-fluorodeoxyglucose to predict
pathologic response after induction chemotherapy and defini-
tive chemoradiotherapy in head and neck cancer.
Head Neck
.
2004;26:890-896.
27. Moeller BJ, Rana V, Cannon BA, et al. Prospective risk-
adjusted [18F] fluorodeoxyglucose positron emission tomogra-
phy and computed tomography assessment of radiation response
in head and neck cancer.
J Clin Oncol
. 2009;27:2509-2515.
28. Mori M, Tsukuda M, Horiuchi C, et al. Efficacy of fluoro-2-
deoxy-D-glucose positron emission tomography to evaluate
responses to concurrent chemoradiotherapy for head and neck
squamous cell carcinoma.
Auris Nasus Larynx
. 2011;38:724-729.
29. Nam SY, Lee S-W, Im KC, et al. Early evaluation of the
response to radiotherapy of patients with squamous cell carci-
noma of the head and neck using 18 FDG-PET.
Oral Oncol
2005;41:390-395.
30. Nayak JV, Walvekar RR, Andrade RS, et al. Deferring
planned neck dissection following chemoradiation for stage IV
Cheung et al
32